 treatment patient advanc colorect cancer cisplatin leucovorin vitro studi synergi LV cisplatin cddp human colon cancer cell line clinic trial effect combin patient advanc unresect colorect carcinoma fifty-nin patient studi prior convent chemotherapi treatment weekli cours high-dos LV intraven IV bolu cddp infus consecut day median treatment cycl object tumor respons patient complet remiss respons rate untreat patient confid limit stabl diseas patient tumor patient median surviv time month patient year regimen primari side effect mild revers gastrointestin symptom myelosuppress episod life-threaten toxic eastern cooper oncolog group ecog grade iii advers reaction dose reduct patient result trial LV cddp activ safe well-toler combin regimen patient advanc colorect cancer